F182112 + pomalidomide

F182112 + pomalidomide is an investigational combination therapy being developed by Shandong New Time Pharmaceutical for the treatment of relapsed or refractory multiple myeloma (RRMM). F182112 is a bispecific monoclonal antibody designed to target B-cell maturation antigen (BCMA) on the surface of myeloma cells and the CD3 receptor on T cells, thereby redirecting T-cell cytotoxic activity to induce tumor cell lysis. Pomalidomide is an immunomodulatory imide drug (IMiD) that acts as a molecular glue, binding to the cereblon (CRBN) E3 ubiquitin ligase complex to promote the degradation of transcription factors such as Ikaros (IKZF1) and Aiolos (IKZF3), which enhances immune cell function and exerts direct anti-proliferative effects on myeloma cells. The combination is currently being evaluated in Phase II clinical trials for patients who have failed prior therapies, including lenalidomide and proteasome inhibitors, aiming to leverage the synergistic effects of T-cell engagement and immunomodulation.

Other names

F182112 plus pomalidomideF-182112 plus pomalidomideF 182112 plus pomalidomide